menu
    • menu
    [{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Won & Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"Supernova 1","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Won & Partners","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Won & Partners"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CAL1 vaccinia virus","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Cerecor","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CERC-006","moa":"mTOR 1\/2 complex","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calidi Biotherapeutics \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Calidi Biotherapeutics \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"NNV1","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Calidi Biotherapeutics \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"City of Hope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Allogeneic Neural Stem Cell","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AD-MSC Based Oncolytic Virus","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AD-MSC Based Oncolytic Virus","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"AD-MSC-based Oncolytic Virus","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ CIRM","highestDevelopmentStatusID":"4","companyTruncated":"Calidi Biotherapeutics \/ CIRM"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Jackson Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"NSC-CRAd-S-pk7","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Calidi Biotherapeutics \/ Jackson Investment Group","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ Jackson Investment Group"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NSC.CRAd-S-pk7","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Calidi Biotherapeutics \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Calidi Biotherapeutics \/ City of Hope"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Calidi Biotherapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann","highestDevelopmentStatusID":"5","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann","highestDevelopmentStatusID":"7","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CLD-400","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ SIGA Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Calidi Biotherapeutics \/ SIGA Technologies"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CLD-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Calidi Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calidi Biotherapeutics","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"CLD-101","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Calidi Biotherapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"14","companyTruncated":"Calidi Biotherapeutics \/ Ladenburg Thalmann & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Calidi Biotherapeutics

    Menu

    Calidi Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLD-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Ladenburg Thalmann & Co

                            Deal Size : $2.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Calidi Biotherapeutics Prices $2M Registered Offering And Placement

                            Details : Calidi intends to use the net proceeds from the offerings for clinical development of CLD-101, which is being evaluated for the treatment of Glioma.

                            Brand Name : CLD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 23, 2024

                            Lead Product(s) : CLD-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Ladenburg Thalmann & Co

                            Deal Size : $2.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLD-101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Calidi Biotherapeutics Receives FDA Clearance for CLD-101 in High-Grade Glioma

                            Details : CLD-101 is a novel stem-cell based platform designed to deliver oncolytic viruses to tumors. It is beinf evaluated for the treatment of newly diagnosed high grade glioma.

                            Brand Name : CLD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 30, 2024

                            Lead Product(s) : CLD-101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLD-400

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : SIGA Technologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Calidi Collaborates with SIGA to Advance RTNova Virotherapy for Lung Cancer

                            Details : The collaboration aims to support the development of Calidi’s systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.

                            Brand Name : CLD-400

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 10, 2024

                            Lead Product(s) : CLD-400

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : SIGA Technologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLD-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Ladenburg Thalmann

                            Deal Size : $2.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

                            Details : The company intends to use the net proceeds from this offering to advance the clinical development of NeuroNova (CLD-101) for treating high-grade glioma.

                            Brand Name : CLD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 31, 2024

                            Lead Product(s) : CLD-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Ladenburg Thalmann

                            Deal Size : $2.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLD-101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Ladenburg Thalmann

                            Deal Size : $6.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

                            Details : The net proceeds will be used for the advancement of company's CLD-101 designed to protect and better distribute the anti-cancer virus to sites of tumors distant from the main tumor mass.

                            Brand Name : CLD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 19, 2024

                            Lead Product(s) : CLD-101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Ladenburg Thalmann

                            Deal Size : $6.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NSC.CRAd-S-pk7

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : City of Hope

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Calidi Biotherapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Clinical Trial Evaluating Ne...

                            Details : CLD-101 platform, which includes NSC.CRAd-S-pk7, is an allogeneic, “off-the-shelf” therapy comprised of an immortalized NSC line loaded with an engineered oncolytic adenovirus.

                            Brand Name : CLD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 18, 2023

                            Lead Product(s) : NSC.CRAd-S-pk7

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : City of Hope

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NSC-CRAd-S-pk7

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Jackson Investment Group

                            Deal Size : $25.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Plat...

                            Details : The financing will enable Calidi to continue the advancement of its pipeline including CLD-101, CLD-201, and CLD-202, which utilize a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.

                            Brand Name : CLD-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 23, 2023

                            Lead Product(s) : NSC-CRAd-S-pk7

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Jackson Investment Group

                            Deal Size : $25.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AD-MSC-based Oncolytic Virus

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : CIRM

                            Deal Size : $3.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Adva...

                            Details : SNV1 is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC Based Oncolytic Virus) loaded with the oncolytic vaccinia virus Cal1, targeting a variety of solid tumors including metastatic melanoma, triple negative breast cancer, and adv...

                            Brand Name : SNV1

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 14, 2022

                            Lead Product(s) : AD-MSC-based Oncolytic Virus

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : CIRM

                            Deal Size : $3.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AD-MSC Based Oncolytic Virus

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Calidi Biotherapeutics to Present Pre-Clinical SuperNova1 (SNV1) Data at the 2022 SITC Annual Meeting

                            Details : SNV1 (AD-MSC based oncolytic virus) is an AD-MSC-delivering CAL1 oncolytic virus used for the treatment of solid tumors (metastatic breast, melanoma, head and neck).

                            Brand Name : SNV1

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 12, 2022

                            Lead Product(s) : AD-MSC Based Oncolytic Virus

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Calidi Biotherapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AD-MSC Based Oncolytic Virus

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Calidi Biotherapeutics Granted U.S. Patent for Proprietary Therapeutic Delivery Platform, Strengthening Compan...

                            Details : The SNV platform is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC) loaded with an oncolytic agent, such as the vaccinia virus SNV1, and is anticipated to be used in combination with various immunotherapy agents, including blockin...

                            Brand Name : SNV1

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 24, 2022

                            Lead Product(s) : AD-MSC Based Oncolytic Virus

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth